Aduro's bolus of new investors

Aduro BioTech Inc. cashed in on an eventful 2014 by adding $51.4 million that Chairman, President and CEO Stephen Isaacs said gives the cancer immunotherapy company the ability to expand clinical activities "well into 2017."

The cash came in an untranched series D round last week from new investors that included OrbiMed, Janus Capital Management, Franklin Advisers, Jennison Associates, Foresite Capital Management and Clough Capital Partners...